PH1 is a rare genetic disorder characterized by excessive production of oxalate, leading to kidney stones, kidney failure, and other systemic complications. IPX-461 has shown promise in reducing urinary oxalate excretion and improving kidney function in patients with PH1.
Like all medications, IPX-461 is not without potential side effects. Some of the common side effects reported in clinical trials include: IPX-461